Biotechnology - Rare diseases, Respiratory and Pulmonary

Filter

Popular Filters

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

FTC files Amicus Brief, saying improper use of restricted drug distribution programs may impede generic competition

13-03-2013

The US Federal Trade Commission has filed an amicus brief in the US District Court for the District of…

ActavisActelionApotexBiotechnologyGenericsLegalNorth AmericaRare diseasesRespiratory and PulmonaryRoxaneTracleerZavesca

Gilead abandons development of PAH drug cicletanine

23-08-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued…

BiotechnologycicletanineGilead SciencesRare diseasesResearchRespiratory and Pulmonary

Germany’s IQWIG negative on InterMune’s Esbriet

18-12-2011

US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

Company Spotlight

ImmunoGen

ImmunoGen

Back to top